Dupilumab (Dupixent®) for severe asthma (children 6 to 11 years old). HTA ID: 23044

Assessment Status Rapid Review Complete
HTA ID 23044
Drug Dupilumab
Brand Dupixent®
Indication Dupilumab (Dupixent®) is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.
Assessment Process
Rapid review commissioned 24/07/2023
Rapid review completed 05/09/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.